Pharma Distribution M&A Opportunity
Having unlocked the next case study of this Theme Vitrine , here is the deal:
Mongolia
“Mongolia’s land area is roughly equivalent to that of the countries of western and central Europe” and it is surrounded by other giants in the form of China, Russia and Kazakhstan. Yet it has only 3.3 million people and 4x the sheep heads.
Its main economic activity and driver is mining with a share of almost a quarter of the GDP. For example: “Oyu Tolgoi is one of the largest known copper and gold deposits in the world”It is largely an export-import-dependent nation with the bulk of its exports sold to China in the form of coal and copper, both having negative direct land & indirect health effects from excavation.By contrast, health and education have been focal to every government in Mongolia (all democratically elected since the 90s!), with the healthcare expenditure rising to over $500 per capita.Despite state-owned health facilities being a regular occurrence in Mongolia, the private sector has grown in importance. So for example, even the former state incumbent distributor MEIC (Mongol Em Impex Concern established in 1923) was privatized to Bishrelt Holding in 2006.
Mongolian pharma market is formed by:
40 local producers
Local production mainly consists of small producers producing old generics, traditional medicines & vitamins, with Monos and some foreign JVs being exceptions rather than a rule
120 wholesalers
Top 10 wholesale pharma distributors / importers take over 80% of the market: MEIC, Monos, Asiapharma, Ento, Europharma, Munkhiin Tun, Dakalpharma, Ombol, Monpha Trade, Tsahiur Tomor
1,300 retailers
250 outlets within state-owned hospitals, 250 pharmacies part of a chain/retail network such as Monos, and the rest independent outlets licensed by individual pharmacists
60 source-countries of imports
Russia, Germany, Slovenia, Hungary, India, Bulgaria, France, Austria, S.Korea, China… (most of the raw material comes from China and S.Korea)
An estimated 15-20% of pharma products are sold illegally in the country, a similar estimate to that of Kyrgyzstan pharma market.
Photo:BH
Mongolia’s pharmaceuticals sector has doubled over the last decade, from about $60mil to about $100mil, depending on the definition. This translates to +/-$30 per capita, still leaving a significant upside to catch up to comparable peers. So for example this in line where neighbouring Kazakhstan @ $32/cap was 12 years ago.
All in line with pharma consumption being very much related to increasing living standards, whereby health consciousness translates to a stronger demand for preventive medicine, food supplements and vitamins.
Currently, Mongolian drug consumption is still very much a developing world type, with the top five categories being antibiotics, digestives, cardiovascular, neurotropic & respiratory medicines.
There are seven government bodies or agencies involved in the pharma market regulation, which can be viewed as relatively lenient compared to some peer countries. The following functions and/or periodic (re)licensing / review / approval: licensing of manufacturing, licensing of importation, licensing of wholesale, licensing of retail, product assessment and registration, GMP Inspection, inspection of distribution channels, import control, quality control of products, control of medicines promotion& advertising, price control for the essential list, generic substitution, control of prescribing, technical elements (standards, norms, guidelines, procedures).
Monos is a family business started by brother and sister Luvsan in 1990, as a small pharma & cosmetics workshop producing skin treatment creams, powders and solutions for respiratory diseases using local herbal ingredients.
Being a pharmacologist by training, educated in the former USSR, the brother was an industry insider having worked for the Pharmaceuticals Institute and MEIC, a former state import & distribution monopoly.
It has diversified into other sectors over the last decade but with pharmaceuticals still at its heart. With 1,600 employees and 30 businesses, the group as a whole is a significant contributor to employment and state taxes.
Photo:BB
Monos operates a nationwide wholesale & distribution network, and a pharmacy chain (mainly in Ulaanbaatar and Central Mongolia). It also has a number of drug-, cosmetic- & health-foods-making facilities, which manufacture approx.100 types of medicines including 30 own brands. The retail chain has 90 pharmacy stores, a roughly equivalent amount to the incumbent competitor.
Mr. Luvsan / Monos won a number of state awards including for scientific research on kidneys and immune booster development. Given that the country relies on 80% of its drug consumption from imports, a rare event is that its own brand Nefromon is exported to Russia since 2014. Today the business has a pharma academy and medical research centres for bolstering innovation and future growth.
Production technology, WHO GMP-compliant and financed by the EBRD, allows for manufacturing of plain tablets, coated tablets, galen, capsules, powder, pills, cream, talcum powder, liquid, extract & syrup.
Monos’ pharmaceutical market share is probably at about a third of what is estimated to be just about a $100mil total pharma market, depending on the definition. Whereby being a straight-out leader in local production, which in total accounts for less than 20% of pharmaceutical demand in the country; a joint co-leader in wholesale with the sate MEIC; and a top player in the fragmented retail space.
Probably operating at a consolidated pharma EBITDA of 15-20%, where profitability from better to worse goes from own production to drug wholesale to retail outlets.
Given Mongolia’s landlocked status & relative isolation, its harsh winters with related seasonality, and high import dependence coupled with relative unfavourable supplier terms given the size of the production & overall significance in world markets- pharma business should have a longer asset conversion cycle than some comparable peer countries.
Managing working capital where a lot of cash is tied up, and in particular inventory turnover, is of great importance for its distribution units. At perceived volumes, modernised facilities and installed ERP, inventory days-on-hand should probably aim at (+/-): 100 days for the main warehouse, with logistics sub-points & city outlets at around 25 days, while areas outside Ulaanbaatar should be allowed up to 75 days.
The company should be well bankable (strong fixed asset base, reasonable net debt, predictable & growing cash flow, etc.), if it did not get too playful with the non-core businesses, and should be easily able to organically operate solely with the local financial institutions. It also does not look like that Monos has potential problems with succession, as it remains largely an extended family affair. On the other hand, it could have going public potential.!?
Theme Contribution
Madina Umarova
Experienced consultant with a demonstrated history of working in the industry. Skilled in commercial and nonprofit activity. Strong in business development, HR, marketing and administration.
Madina also is:
- Vice president, head of economic group (CIS), Coordinating Council of Russian compatriots in Croatia
- Founder of the Russian culture club in Croatia
- Teacher of Russian language and literature (& business comm)
And was:
- KPMG senior office administrator
- Professor at Law university
- Club administrator
- Cello instructor
Theme Related Tracker
- Model reveals strategies to modify the tumor microenvironment and improve cancer therapy
on October 9, 2026Researchers from Mass General Brigham and the University of Cyprus have developed a sophisticated mathematical model to better understand how the tumor microenvironment affects the delivery and effectiveness of a new type of cancer therapy called an immunomodulatory antibody-drug conjugate (IM-ADC).
- Blocking immune cells' path into brain limits neurodegenerationon October 8, 2026
There is no treatment available today to stop the death of brain cells in neurodegenerative diseases known as tauopathies, including Alzheimer’s disease, in which twisted clumps of a protein called tau accumulate in the brain. Cells near those clumps begin to die after tau accumulates, but growing evidence suggests that much of the damage doesn’t come from the protein directly.
- Frequent cannabis use tied to more severe epilepsyon October 7, 2026
Adults with hard-to-treat epilepsy who used cannabis most days had more than twice as many convulsive seizures per year and more rapidly became resistant to antiseizure medications compared with nonusers, according to new research from Washington University School of Medicine in St. Louis. The study appears in the journal Epilepsia.
- A new technique could accelerate the development of RNA therapieson October 6, 2026
RNA vaccines and other nucleic acid therapeutics are typically packaged within fatty molecules known as lipid nanoparticles (LNPs). MIT researchers have now come up with a way to produce these particles much more quickly, and with more precise control over their size and shape.
- The concentration of pharmaceuticals in the blood in under 10 minuteson October 5, 2026
Minutes count when a patient with a stroke arrives at the hospital emergency room. Doctors stand ready to treat, but whether the blood clot can be removed medically depends on what medication the patient is already taking. Even if a blood sample is rushed through the laboratory, results can take up to an hour to arrive.
- Can AI find drugs to fight infection?on October 2, 2026
Streptococcus pneumoniae is a bacterial pathogen that causes life-threatening infections, including pneumonia and meningitis. These infections are commonly treated with antibiotics, but antibiotics are becoming less effective against S. pneumoniae over time due to changes in the pathogen that cause drug resistance. This phenomenon, called antimicrobial resistance, is resulting in significant healthcare costs and deaths around the world.
- How interferon changes cancerous blood stem cellson October 1, 2026
The biologic drug interferon-alpha can benefit patients with blood cancers called myeloproliferative neoplasms by forcing mutant blood stem cells to become shorter-lived white blood cells, according to a study by Weill Cornell Medicine investigators. Because the broad activity of interferon-alpha can induce significant side effects,
- New US Medicare pricing policies could reshape global pharmaceutical marketson September 30, 2026
New US Medicare pricing policies could reshape global pharmaceutical markets, potentially driving up prices and delaying medicine launches worldwide, study suggests. A new modelling study published in The Lancet suggests that US Medicare's new 'Most-Favoured-Nation' pricing policy [1], which ties what Medicare pays for medicines to prices charged in other high-income countries,
- Pfizer advances today's cancer care and tomorrow's potential breakthroughs at ESMO
on September 29, 2026Pfizer Inc. (NYSE: PFE) will present data from 45 company-sponsored, investigator-sponsored, and collaborative research abstracts at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026 in Madrid, Spain. The presentations include 11 oral presentations spanning Pfizer’s established medicines and late-stage pipeline across its disease areas of focus, including breast cancer, genitourinary cancers, and lung cancer.
- Experimental study points to systemic sclerosis treatmenton September 28, 2026
Investigators at Cedars-Sinai Health Sciences University used an experimental drug to reverse the effects of systemic sclerosis, a serious autoimmune disease. The study, conducted in a laboratory, was published in JCI Insight. Systemic sclerosis, also called scleroderma, is a chronic, life-threatening condition that scars the skin, lungs, heart and other organs.
